Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00233519 · ClinicalTrials.gov registry record · Phase 1
Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1)
A Phase 1 study of Myotonic Dystrophy, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT00233519 is a Phase 1 study of Myotonic Dystrophy that has completed, run by University of Rochester. The registered enrollment target is 17 participants, below the 854-participant average among 9 other Myotonic Dystrophy trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00233519, a Phase 1 study of Myotonic Dystrophy, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this study is to investigate the safety and feasibility of daily subcutaneous injections of recombinant IGF1 complexed with IGF binding protein 3 (SomatoKine-INSMED) as a treatment for muscle wasting and weakness in myotonic dystrophy type 1.
Conditions Studied
Interventions
- DRUG SomatoKine/IPLEX
Study Locations (1)
New York
- University of Rochester Medical Center - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2005-11 |
| Est. Completion | 2008-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00233519
The ClinicalTrials.gov registry entry for NCT00233519 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 854-participant average among 9 other Myotonic Dystrophy trials with a reported enrollment target (98% lower). The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myotonic Dystrophy appearing as the primary indexed condition, and to 1 intervention - of which SomatoKine/IPLEX is the first listed.
NCT00233519 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00233519 about?
NCT00233519 is a clinical study titled "Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1)". The aim of this study is to investigate the safety and feasibility of daily subcutaneous injections of recombinant IGF1 complexed with IGF binding protein 3 (SomatoKine-INSMED) as a treatment for muscle wasting and weakness in myotonic dystrophy type 1.
What is the current status of trial NCT00233519?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2005-11. Estimated completion is 2008-05.
What conditions does trial NCT00233519 study?
This clinical trial studies the following conditions: Myotonic Dystrophy.
What interventions are being tested in trial NCT00233519?
The interventions under investigation include: SomatoKine/IPLEX (DRUG).
Who is sponsoring clinical trial NCT00233519?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00233519 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myotonic Dystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 50 Years of Age With Non-congenital Myotonic Dystrophy Type 1
RECRUITING · Phase 1
-
Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
RECRUITING
-
Biomarker Development for Muscular Dystrophies
RECRUITING
-
Development of Quantitative Muscle Imaging as a Biomarker of Disease Endpoints in Myotonic Dystrophy
RECRUITING
-
Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy Extension
RECRUITING
-
Extracellular RNA Biomarkers of Myotonic Dystrophy
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.